It has been observed that cancer cells, by substantially enhancing the rate of glucose influx via activating enzymes involved in the reactions converting glucose to PEP (from HK to ENO), and the attenuation of the last step, the conversion of PEP to pyruvate, by expression of the PKM2 isoform of which the velocity can be allosterically regulated, allow a greater flow of glycolytic intermediates to many biosynthetic routes. The gene discussed is HK1; the disease is cancer.